Statements of support for Global Drug Facility (GDF)

United States Agency for International Development

"I want to congratulate the Stop TB Partnership and the Global Drug Facility on this very impressive achievement. Poor quality anti-TB drugs are a barrier to preventing and eliminating tuberculosis (TB), which kills about 1.6 million people each year. The Global TB Drug Facility has provided effective treatment for 10 million people with TB in 78 countries, saving countless lives. For a devastating disease that is often diagnosed late, treated improperly or not treated at all, this is a significant accomplishment and an excellent example of what strong commitment and coordinated action can achieve. With continued focus and action by country programs, the international community, and the Stop TB Partnership, we can stop this disease and save lives.

"I am proud that the U.S. Agency for International Development (USAID) is a key partner in this global effort to Stop TB and to the Global Drug Facility. In addition, we remain strong supporters of the Global TB Drug Facility and we are fully committed to supporting country level TB programs to ensure patients have access to high quality care and the needed support to complete treatment, together with our continuing investments in new TB drugs and diagnostics. We have a public health and moral imperative to fully implement The Global Plan to STOP TB. If that is done, 50 million people will be treated for TB and 800,000 people for multi-drug resistant (MDR) TB, and 14 million lives will be saved by 2015."

Dr. Kent Hill
Assistant Administrator, Global Health
United States Agency for International Development

Global Fund to Fight AIDS, Tuberculosis and Malaria

"I congratulate the Stop TB Partnership on this accomplishment. The Global Drug Facility and the Global Fund together provide countries with financing and drugs that ensure better-run programmes and a continuous drug supply so that more patients take a full course of treatment, thereby lowering the risk of drug-resistant TB."

Dr. Michel Kazatchkine
Executive Director
The Global Fund to Fight AIDS, Tuberculosis and Malaria

Management Sciences for Health

"Since 2000, Management Sciences for Health (MSH) has partnered with the Global Drug Facility (GDF) to promote its mission and objectives of bringing TB medicines to countries unable to procure or finance their full medicine requirements. GDF has had good program leadership through the Stop TB Partnership, while MSH as a not for profit organization has been fortunate to have the opportunity to provide technical assistance and leadership through financial support of its donors USAID (through the Rational Pharmaceutical Management Plus Program) and the Bill & Melinda Gates Foundation (through the Strategies for Enhancing Access to Medicines Program).

"Upon request of the GDF, MSH seconded a pharmaceutical management specialist and a procurement officer who have helped the GDF not only reach its objectives but also expand them to include technical assistance in developing new products and new
services such as the Stop TB Patient Kit, the laboratory diagnostic kits, paediatric formulations, provision of in-country technical assistance to national TB programs and support of the WHO Prequalification program for qualifying TB medicine suppliers.

“As demands for GDF supplies and services have skyrocketed MSH likewise increased its support which has resulted in regional workshops in pharmaceutical management for TB, training of TB consultants to carry out GDF missions to recipient countries and supporting consultants on GDF country visits.

"GDF has gained valuable experience over the years and others are already using the GDF model for providing commodities and services to counter other health problems. MSH is proud to support the GDF as it continues its invaluable services directed at alleviating the problem of TB worldwide."

Management Sciences for Health

"Stop TB and the Global Drug Facility are helping get life-saving drugs to people today. There is a desperate need for new drugs to shorten and simplify TB treatment, but tomorrow's drugs will only be effective if they reach patients. Our just-released study, Pathway to Patients: Charting the Dynamics of the Global TB Drug Market, highlights the critical supply chain issues affecting TB drug delivery and the need for collaborative action to provide long-term, sustainable mechanisms to ensure that new TB drugs are available to those who need them."

Maria C. Freire, CEO and President of the Global Alliance for TB Drug Development